545 related articles for article (PubMed ID: 29777655)
1. Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS).
Kolstad KD; Li S; Steen V; Chung L;
Chest; 2018 Oct; 154(4):862-871. PubMed ID: 29777655
[TBL] [Abstract][Full Text] [Related]
2. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry.
Chung L; Domsic RT; Lingala B; Alkassab F; Bolster M; Csuka ME; Derk C; Fischer A; Frech T; Furst DE; Gomberg-Maitland M; Hinchcliff M; Hsu V; Hummers LK; Khanna D; Medsger TA; Molitor JA; Preston IR; Schiopu E; Shapiro L; Silver R; Simms R; Varga J; Gordon JK; Steen VD
Arthritis Care Res (Hoboken); 2014 Mar; 66(3):489-95. PubMed ID: 23983198
[TBL] [Abstract][Full Text] [Related]
3. Survival in systemic sclerosis-pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry.
Hinchcliff M; Khanna S; Hsu VM; Lee J; Almagor O; Chang RW; Steen V; Chung L;
Semin Arthritis Rheum; 2015 Dec; 45(3):309-14. PubMed ID: 26210782
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population.
Hinchcliff M; Fischer A; Schiopu E; Steen VD;
J Rheumatol; 2011 Oct; 38(10):2172-9. PubMed ID: 21844142
[TBL] [Abstract][Full Text] [Related]
5. Mortality and hospitalization outcomes of interstitial lung disease and pulmonary hypertension in the Singapore systemic sclerosis cohort.
Noviani M; Saffari SE; Tan JL; Yip JWL; Teng GG; Law WG; Chan GYL; Santosa A; Lim AYN; Hong C; Ng SA; Tay ELW; Ruan W; Yap J; Low AHL
Semin Arthritis Rheum; 2020 Jun; 50(3):473-479. PubMed ID: 31810742
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors of mortality and 2-year survival analysis of systemic sclerosis with pulmonary arterial hypertension in Thailand.
Foocharoen C; Nanagara R; Kiatchoosakun S; Suwannaroj S; Mahakkanukrauh A
Int J Rheum Dis; 2011 Aug; 14(3):282-9. PubMed ID: 21816025
[TBL] [Abstract][Full Text] [Related]
7. Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study.
Hsu VM; Chung L; Hummers LK; Wigley F; Simms R; Bolster M; Silver R; Fischer A; Hinchcliff ME; Varga J; Goldberg AZ; Derk CT; Schiopu E; Khanna D; Shapiro LS; Domsic RT; Medsger T; Mayes MD; Furst D; Csuka ME; Molitor JA; Alkassab F; Steen VD
Semin Arthritis Rheum; 2014 Aug; 44(1):55-62. PubMed ID: 24709277
[TBL] [Abstract][Full Text] [Related]
8. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.
Allanore Y; Borderie D; Avouac J; Zerkak D; Meune C; Hachulla E; Mouthon L; Guillevin L; Meyer O; Ekindjian OG; Weber S; Kahan A
Arthritis Rheum; 2008 Jan; 58(1):284-91. PubMed ID: 18163505
[TBL] [Abstract][Full Text] [Related]
9. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and survival of systemic sclerosis patients with pulmonary hypertension and elevated wedge pressure: Observations from the PHAROS cohort.
Lammi MR; Saketkoo LA; Gordon JK; Lauto P; Fagan K; Steen VD;
Respirology; 2017 Oct; 22(7):1386-1392. PubMed ID: 28500695
[TBL] [Abstract][Full Text] [Related]
11. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival.
Humbert M; Yaici A; de Groote P; Montani D; Sitbon O; Launay D; Gressin V; Guillevin L; Clerson P; Simonneau G; Hachulla E
Arthritis Rheum; 2011 Nov; 63(11):3522-30. PubMed ID: 21769843
[TBL] [Abstract][Full Text] [Related]
12. Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease.
Volkmann ER; Saggar R; Khanna D; Torres B; Flora A; Yoder L; Clements PJ; Elashoff RM; Ross DJ; Agrawal H; Borazan N; Furst DE; Saggar R
Arthritis Rheumatol; 2014 Jul; 66(7):1900-8. PubMed ID: 24729406
[TBL] [Abstract][Full Text] [Related]
13. Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial Hypertension.
Lammi MR; Mathai SC; Saketkoo LA; Domsic RT; Bojanowski C; Furst DE; Steen VD;
Arthritis Rheumatol; 2016 Mar; 68(3):740-8. PubMed ID: 26479414
[TBL] [Abstract][Full Text] [Related]
14. Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis.
Moinzadeh P; Bonella F; Oberste M; Weliwitage J; Blank N; Riemekasten G; Müller-Ladner U; Henes J; Siegert E; Günther C; Kötter I; Pfeiffer C; Schmalzing M; Zeidler G; Korsten P; Susok L; Juche A; Worm M; Jandova I; Ehrchen J; Sunderkötter C; Keyßer G; Ramming A; Schmeiser T; Kreuter A; Lorenz HM; Hunzelmann N; Kreuter M
Chest; 2024 Jan; 165(1):132-145. PubMed ID: 37582424
[TBL] [Abstract][Full Text] [Related]
15. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.
Michelfelder M; Becker M; Riedlinger A; Siegert E; Drömann D; Yu X; Petersen F; Riemekasten G
Clin Rheumatol; 2017 Feb; 36(2):381-390. PubMed ID: 28028682
[TBL] [Abstract][Full Text] [Related]
16. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis.
Lefèvre G; Dauchet L; Hachulla E; Montani D; Sobanski V; Lambert M; Hatron PY; Humbert M; Launay D
Arthritis Rheum; 2013 Sep; 65(9):2412-23. PubMed ID: 23740572
[TBL] [Abstract][Full Text] [Related]
17. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry.
Chung L; Farber HW; Benza R; Miller DP; Parsons L; Hassoun PM; McGoon M; Nicolls MR; Zamanian RT
Chest; 2014 Dec; 146(6):1494-1504. PubMed ID: 24992469
[TBL] [Abstract][Full Text] [Related]
18. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era.
Launay D; Sitbon O; Hachulla E; Mouthon L; Gressin V; Rottat L; Clerson P; Cordier JF; Simonneau G; Humbert M
Ann Rheum Dis; 2013 Dec; 72(12):1940-6. PubMed ID: 23178295
[TBL] [Abstract][Full Text] [Related]
19. Survival in systemic sclerosis associated pulmonary arterial hypertension in the current treatment era-results from a nationwide study.
Sarı A; Satış H; Ayan G; Küçükşahin O; Kalyoncu U; Fidancı AA; Ayvalı MO; Ata N; Ülgü MM; Birinci Ş; Akdoğan A
Clin Rheumatol; 2024 Jun; 43(6):1919-1925. PubMed ID: 38676757
[TBL] [Abstract][Full Text] [Related]
20. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension.
Campo A; Mathai SC; Le Pavec J; Zaiman AL; Hummers LK; Boyce D; Housten T; Champion HC; Lechtzin N; Wigley FM; Girgis RE; Hassoun PM
Am J Respir Crit Care Med; 2010 Jul; 182(2):252-60. PubMed ID: 20339143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
